RESUMO
The diagnosis of malignant pleural mesothelioma is difficult, with the most common differential diagnoses being benign pleural diseases and metastatic adenocarcinomas (ADCA). To identify novel markers that would be able to improve diagnostic accuracy, we performed a genome-wide gene expression analysis on tumor cell lines established from pleural effusions (malignant pleural mesothelioma and lung ADCA). This analysis led to the identification of genes encoding novel and pertinent cellular and soluble markers, for which the expression was validated by real-time RT-PCR. Immunohistochemical staining of tumor biopsy specimens with anti-type III collagen antibodies showed positive labeling for mesothelioma cells but not for ADCA cells. Using enzyme-linked immunosorbent assay, we showed that the C-C motif chemokine 2 (CCL2) concentration was significantly higher in pleural effusions from patients with mesothelioma (n = 61) than in subjects with ADCA (n = 25) or with benign pleural effusions (n = 15): median (interquartile range) = 2.99 ng/ml (1.76 to 6.01) vs 0.99 ng/ml (0.51 to 1.83) and 1.47 ng/ml (0.80 to 1.56), respectively, P < 0.0001. Conversely, the galectin-3 concentration was lower in mesothelioma: 11.50 ng/ml (6.73 to 23.53) vs 24.74 ng/ml (20.42 to 70.35) and 17.64 ng/ml (14.81 to 24.68), respectively, P < 0.0001. The areas under the curve for CCL2 were 0.8030 and 0.7716 for the differentiation of mesothelioma from ADCA or benign pleural effusions, respectively. Similarly, the areas under the curve obtained for galectin-3 were 0.7980 and 0.6923, respectively. In conclusion, type III collagen, CCL2, and galectin-3 are promising new diagnostic markers for mesothelioma.
Assuntos
Biomarcadores Tumorais/metabolismo , Mesotelioma/diagnóstico , Neoplasias Pleurais/diagnóstico , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Adenocarcinoma/patologia , Idoso , Quimiocina CCL2/metabolismo , Análise por Conglomerados , Colágeno Tipo III/genética , Colágeno Tipo III/metabolismo , Feminino , Galectina 3/metabolismo , Perfilação da Expressão Gênica , Regulação Neoplásica da Expressão Gênica , Humanos , Imuno-Histoquímica , Masculino , Mesotelioma/genética , Mesotelioma/patologia , Análise de Sequência com Séries de Oligonucleotídeos , Derrame Pleural Maligno/genética , Derrame Pleural Maligno/patologia , Neoplasias Pleurais/genética , Neoplasias Pleurais/patologia , Reprodutibilidade dos TestesRESUMO
Elevated amounts of soluble mesothelin-related proteins (SMRP) have already been reported in sera and pleural effusions from mesothelioma patients, providing a useful diagnostic marker for malignant pleural mesothelioma (MPM). However, the origin of SMRP is not yet understood. Production of SMRP could be related to abnormal splicing events leading to synthesis of a secreted protein (release) or to an enzymatic cleavage from membrane-bound mesothelin (ectodomain shedding). To test these hypotheses, we used a panel of mesothelioma cells established in culture from pleural effusions of MPM patients. Our in vitro results confirmed specific mesothelin expression and SMRP production in supernatants from epithelioid MPM cell lines, thus providing a relevant cellular model to study soluble mesothelin production mechanisms. The expression of mesothelin-encoding RNA variants was screened by reverse transcription-polymerase chain reaction experiments. Protease involvement in mesothelin cleavage from the cellular surface was investigated by treatment of MPM cells with GM6001, a broad-spectrum MMP- and ADAM-family inhibitor. GM6001 treatment significantly impaired SMRP production by MPM cell lines, in favor of an enzymatic-mediated shedding process. In addition, a splice variant transcript of mesothelin (variant 3) was detected in these MPM cell lines, in accordance with the release of a secreted part of the protein. Our results indicate that both mechanisms could be implicated in soluble mesothelin production by epithelioid mesothelioma cells.
Assuntos
Glicoproteínas de Membrana/metabolismo , Mesotelioma/metabolismo , Peptídeo Hidrolases/metabolismo , Neoplasias Pleurais/metabolismo , Splicing de RNA , Linhagem Celular Tumoral , Células Epiteliais/enzimologia , Células Epiteliais/metabolismo , Proteínas Ligadas por GPI , Humanos , Glicoproteínas de Membrana/genética , Mesotelina , Mesotelioma/enzimologia , Mesotelioma/genética , Neoplasias Pleurais/enzimologia , Neoplasias Pleurais/genéticaRESUMO
Hydroxyurea (HU) and 1-beta-D-arabino-furanosylcytosine (AraC) are two compounds used to inhibit DNA repair in the comet assay and thereby increase its sensitivity. We used RNA synthesis and comet assays to assess the cytotoxic and genotoxic effects of HU and AraC in the HepG2 cells after 1, 5, or 21 h of exposure to concentrations used to inhibit DNA repair. HU was genotoxic between 2 and 10 mM after 1 h of exposure and cytotoxic after 21 h. The presence of AraC (10, 50, or 100 microM) increased the DNA damage caused by HU (10 mM) suggesting a potentiation of the genotoxic effect. The interaction between the two inhibitors started after 5 h but was not dependent on the concentrations of AraC. Consequently, careful attention is required when employing a combination of HU and AraC, as their mechanisms of action could interfere with the interpretation of the data from genotoxicity assays.